Pediatrics Doctors in West Sacramento, CA Accepting Medicare

7 Pediatrics doctors found. Showing 1 - 7

Nancy Warden, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1276 Halyard Dr, West Sacramento, CA 95691 Phone: 855-354-2242

Jessica Cheng, Pediatrics Medicare: Medicare Enrolled Practice Location: 1276 Halyard Dr, West Sacramento, CA 95691 Phone: 916-569-8484

Muthumanimoli Sivakumaran, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1276 Halyard Dr, West Sacramento, CA 95691 Phone: 855-354-2242

Yolanda Santana Tejeda, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2101 Stone Blvd Ste 100, West Sacramento, CA 95691 Phone: 916-371-3787

Harini Racherla, Pediatrics Medicare: Medicare Enrolled Practice Location: 2101 Stone Blvd, #6m, West Sacramento, CA 95691 Phone: 917-704-7844

Olga Kashlinskaya, M.D. Pediatrics - Adolescent Medicine Medicare: Medicare Enrolled Practice Location: 804 Harbor Blvd, West Sacramento, CA 95691 Phone: 916-371-1616    Fax: 916-375-0706

Colleen Callaghan, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 155 15th St, Suite A, West Sacramento, CA 95691 Phone: 916-375-8990

News Archive

Legislation introduced that would give FDA authority to approve generic versions of biotechnology drugs

Lawmakers in the House and Senate on Wednesday introduced a bill that would allow FDA to approve generic versions of biotechnology medications, USA Today reports.

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health. The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

GAVI Alliance pledges up to $162M to control, prevent measles outbreaks in developing countries

"Seeking to address the devastating resurgence of measles, the GAVI Alliance will provide up to an additional $162 million to control and prevent outbreaks in developing countries," a GAVI press release reports, noting, "This funding will help countries bridge critical gaps in their efforts to build sustainable systems to control this deadly disease."

Tengion completes initial 6M common stock public offering

Tengion, Inc., a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share. The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million.

Read more Medical News

› Verified 7 days ago